Evidence map›Paper›PMID 42691041›Full record

ArticlePLoS pathogens2026

A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral particle release and cytopathogenicity.

Inessa Manuelyan, Anna M Schmoker, Boyd L Yount, Philip Eisenhauer, Judith I Keller, Clarissa Gold, Dante Terino, Christopher M Ziegler, Jeff Alexander, Edward Hutchinson and 7 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Inessa ManuelyanDepartment of Medicine, Division of Immunobiology, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Anna M SchmokerDepartment of Biology, University of Vermont, Burlington, Vermont, United States of America.
Boyd L YountDepartment of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America.
Philip EisenhauerDepartment of Medicine, Division of Immunobiology, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Judith I KellerDepartment of Biology, University of Vermont, Burlington, Vermont, United States of America.
Clarissa GoldVermont Biomedical Research Network, University of Vermont, Burlington, Vermont, United States of America.
Dante TerinoDepartment of Medicine, Division of Immunobiology, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Christopher M ZieglerDepartment of Medicine, Division of Immunobiology, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.
Jeff AlexanderVLP Therapeutics, Inc., Gaithersburg, Maryland, United States of America.
Edward HutchinsonMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, Scotland, United Kingdom.
David BhellaMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, Scotland, United Kingdom.
Christopher D SymeMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, Scotland, United Kingdom.
Douglas G WidmanDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States of America.
Mark T HeiseDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States of America.
Ralph S BaricDepartment of Epidemiology, The University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America.
Bryan A BallifDepartment of Biology, University of Vermont, Burlington, Vermont, United States of America.
Jason W BottenDepartment of Medicine, Division of Immunobiology, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America.ORCID 0000-0001-6839-0306

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Julie Dragon · 2012 to 2026
$58.4M
VERMONT IMMUNOBIOLOIGY/ INFECTIOUS DISEASES CENTERP20RR021905 · NCRR · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2006 to 2011
$14.5M
Vermont Immunology/Infectious Diseases CenterP30GM118228 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2016 to 2021
$6.8M
Multidisciplinary Training in Lung BiologyT32HL076122 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI IRVIN, CHARLES G, POYNTER, MATTHEW E · 2004 to 2023
$6.1M
Molecular Basis of Flavivirus Cross-Neutralization by Human AntibodiesR01AI107731 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2013 to 2022
$5.3M
Mapping the Zika virus phosphoproteomeR21AI135265 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BOTTEN, JASON W. · 2018 to 2019
$425k
NCRR NIH HHS P20 RR021905NHLBI NIH HHS T32 HL076122NIAID NIH HHS R01 AI107731NIAID NIH HHS R21 AI135265NIGMS NIH HHS P20 GM103449NIGMS NIH HHS P30 GM118228
6 · The paper itself

Abstract

Flaviviruses are enveloped, positive-strand RNA viruses that cause millions of infections in the human population annually. Although Zika virus (ZIKV) had been detected in humans as early as the 1950s, its reemergence in South America in 2015 resulted in a global health crisis. While flaviviruses encode 10 proteins that can be post-translationally modified by host enzymes, little is known regarding post-translational modifications (PTMs) of the flavivirus proteome. We used mass spectrometry to comprehensively identify host-driven PTMs on the ZIKV proteome. This approach allowed us to identify 43 PTMs across 8 ZIKV proteins, including several that are highly conserved within the Flavivirus genus. Notably, we found two phosphosites on the ZIKV envelope protein that are functionally important for viral propagation. Both appear to regulate viral particle release, while one also impacts ZIKV cytopathogenicity. Additionally, we discovered host kinases that interact with ZIKV proteins and determined that Bosutinib-an FDA-approved tyrosine kinase inhibitor that targets some of these host kinases-impairs ZIKV growth, in part by blocking phosphorylation of a tyrosine residue on the envelope protein. Thus, we have defined a high-resolution map of host-driven PTMs on ZIKV proteins as well as cellular interacting kinases, uncovered novel mechanisms of host driven-regulation of ZIKV particle release and cytopathogenicity, and identified an FDA-approved inhibitor of ZIKV growth.

Indexed as

Host-Pathogen InteractionsPhosphoproteinsProteomeVirus ReleaseZika VirusZika Virus InfectionAnimalsHumansPhosphorylationProtein Processing, Post-TranslationalViral Envelope ProteinsPhosphoproteinsProteomeViral Envelope Proteins

Identifiers

PMID42691041
PMCPMC13541192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.